ビジネスワイヤ(バフェットのBerkshire Hathaway group)

SpinalCyteが新たな日本国特許を取得 2017年07月22日 03時20分

ヒューストン--(BUSINESS WIRE)--テキサスに拠点を置き、ヒト皮膚線維芽細胞を使用した椎間板髄核の再生に傾注する組織工学技術企業のSpinalCyte,
LLC
は本日、日本国特許第6151006号「生体内バイオリアクターを使用した軟骨修復のための方法と組成物」の登録を発表しました。




本特許で記述された技術は、軟骨細胞または軟骨細胞様細胞の細胞/足場組成物の調製に関するものです。本特許ではヒト皮膚線維芽細胞(HDF)を当該足場に適用し、当該線維芽細胞を機械的ストレス、低酸素状態、断続的な静水圧にさらすことを請求項としています。さらに本技術では骨形成成長因子の使用についても記述しています。



SpinalCyteのPete
O’Heeron最高経営責任者(CEO)は、次のように述べています。「この新たな日本国特許は当社の線維芽細胞技術に関して国際的な保護を独自に達成したことを示しており、線維芽細胞を使用して軟骨を再成長させるための当社の国際的な知的財産ポートフォリオを発展させるものです。」



今回の追加により、SpinalCyteのポートフォリオは当社が直接に保有する登録特許(米国・海外)が23件、出願中特許が46件となります。



SpinalCyte, LLCについて



テキサス州ヒューストンに拠点を置くSpinalCyte,
LLCは組織工学技術企業として、ヒト皮膚線維芽細胞を使用した髄核置換のための革新的なソリューションの開発に当たっています。SpinalCyteは現在、米国および海外の登録特許23件を保有し、さらに46件の特許を出願中です。出資のすべてをエンジェル投資家から受けているSpinalCyteは、バイオ医薬品および細胞療法の次世代医療の進歩を象徴しています。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。




Contacts


Investors:
SpinalCyte, LLC
Pete O’Heeron, 281-461-6211
CEO
info@spinalcyte.com
or
Media:
Pierpont
Communications
Brittney Garneau, 713-627-2223
bgarneau@piercom.com



NRI Secure Launches Japan's First "Blockchain Assessment" S… 2017年07月21日 16時00分


- First Step Designed for Smart Contract Security -


TOKYO--(BUSINESS WIRE)--NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI
Secure), a leading provider of information security solutions in Japan,
has begun providing Japan’s first-ever*1 “Blockchain
Assessment,” a security Assessment service designed for systems and
services which use blockchain technology*2.








As the blockchain technology has become more widespread, the presence of
security-related vulnerabilities has also become increasingly apparent.
In particular, with regard to smart contracts, *3 one of a
constituent element of services using the blockchain, a cyberattack
carried out on any vulnerable programs could lead to major threats or
even to actual damage*4 by causing services to behave
differently than originally intended.



In response to these issues, NRI Secure has systematized its accumulated
knowledge and insights in the form of the “Blockchain Assessment”
service. As its first step, NRI Secure will be launching the security
assessment service for smart contracts. The service performs assessment
from the dual perspectives of static analysis, which carefully analyzes
a program, and dynamic analysis, which involves simulating a real
attack, in order to identify vulnerabilities.



More assessment menus for other constituent elements of the blockchain
will be added in the future. (2 to 4 in the overview diagram). This
service is only available in English and Japanese.



NRI Secure continues to provide a variety of products and services for
supporting companies and organizations in their information security
measures, and to contribute to the creation of a safe information system
environment and society on a global scale.



































 

*1

 

First-ever in Japan: This is the first security assessment service
designed specifically for the blockchain to be provided by a medium-
or large-scale security vendor in Japan (according to NRI Secure
research).

*2


Blockchain technology: A technology which achieves a distributed
consensus among its participants and makes it possible to manage
audit trails for all transactions, without the intervention of a
trusted third party. Given such features as its ability to make
falsifying data extremely difficult, its near-zero downtime, its
lack of a centralized manager, and its high transaction performance,
the blockchain has been lauded for being inexpensive to develop and
for its potentially broad application as a way for companies to
exchange information. These features have led to expectations that
the blockchain can be used not only for cryptocurrencies such as
Bitcoin, but as a circulation platform for transactions involving
various asset types. Furthermore, this technology is also gaining
notice for its potential use in the recording and storage of more
common types of contracts, as well as in automatic contract
execution.

*3


Smart contracts: This refers to contracts which are programmed and
can be automatically executed. A smart contract is arranged with the
execution conditions and contractual terms prescribed in advance,
such that the contract is automatically executed when a transaction
occurs matching said conditions. Smart contracts are being
considered for use in securities settlements, real property
transactions, the sharing economy, and numerous other fields that
involve contracts.

*4


Actual damage: “The DAO Incident” occurred on June 17, 2016. Funds
(virtual currency) held by “The DAO,” a virtual corporation
established by a Germany-based venture capital company, were
transmitted to a cyber-attacker who had exploited vulnerabilities in
The DAO’s smart contract programming code.

*5


DApps: This abbreviation stands for Decentralized Applications, and
refers to applications that are decentralized and distributed. They
are said to enable the use of highly-reliably, low-cost applications
via blockchain technology, without the need for a centralized system
manager.

 


About NRI Secure



NRI SecureTechnologies is a subsidiary of Nomura Research Institute
(NRI) specializing in Cybersecurity, and a leading global provider of
next-generation managed security services and security consulting.
Established in 2000, NRI SecureTechnologies is focused on delivering
high-value security outcomes for our clients with the precision and
efficiency that define Japanese quality.
For more details, visit us
at http://www.nri-secure.com



Reference



“Blockchain Assessment” Service




  • Supported platforms: Ethereum, Hyperledger Fabric
    *Additional
    platforms will be supported at a later time.


  • Supported languages: Solidity, Go, Java
    *Please contact us
    regarding any other languages.


  • Price: Estimates will be provided on an individual basis.


  • For more details on the “Blockchain Assessment” Service, please
    contact: info@nri-secure.co.jp.




Contacts


Media Inquiries
NRI SecureTechnologies, Ltd.
Hitomi
Nemoto, +81-3-6706-0622
Public Relations
info@nri-secure.co.jp
Service
Inquiries

NRI SecureTechnologies, Ltd.
Teruhiro Tagomori /
Takenori Kiuchi, +81-3-6706-0622
Cyber Security Services Department
II
info@nri-secure.co.jp



SpinalCyte, LLC Receives New Japanese Patent 2017年07月21日 03時12分

HOUSTON--(BUSINESS WIRE)--#cybrocell--SpinalCyte,
LLC
, a Texas-based tissue engineering technology company focused
on regrowth of the spinal disc nucleus using human dermal fibroblasts,
announced today the issuance of Japanese Patent No. 6151006, “Methods
And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”




The technology described in the patent involves preparing a
cell/scaffold composition wherein the cells are chondrocytes or
chondrocyte-like cells. The patent calls for applying human dermal
fibroblasts (HDFs) to the scaffold and subjecting the fibroblasts to
mechanical stress, hypoxia and intermittent hydrostatic pressure.
Further, the technology described uses a bone morphogenetic growth
factor.



“This new Japanese patent demonstrates the unique international
protection we are achieving with respect to our fibroblast technology
and builds on our international intellectual property portfolio for
using fibroblasts to regrow cartilage.” said Pete O’Heeron, Chief
Executive Officer, SpinalCyte.



With this addition, SpinalCyte’s portfolio now includes 23 U.S. and
foreign patents issued and directly owned by the company, along with 46
patents pending.



About SpinalCyte, LLC



Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering
technology company developing an innovative solution for spinal nucleus
replacement using human dermal fibroblasts. Currently, SpinalCyte holds
23 U.S. and international issued patents and has filed for an additional
46 patents pending. Funded entirely by angel investors, SpinalCyte
represents the next generation of medical advancement for biologics and
cell therapy.




Contacts


Investors:
SpinalCyte, LLC
Pete O’Heeron, 281-461-6211
CEO
info@spinalcyte.com
or
Media:
Pierpont
Communications
Brittney Garneau, 713-627-2223
bgarneau@piercom.com



Takeda and Schrödinger Announce Multi-Year, Multi-Target Re… 2017年07月20日 22時00分


Under novel collaboration approach, Schrödinger will autonomously
lead discovery efforts; Takeda provides complementary structural biology
support and has option to lead development and commercialization of
licensed programs


OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:
4502
) and Schrödinger Inc., a privately-held company dedicated to
revolutionizing drug discovery through advanced computational methods,
today announced the formation of a multi-target research collaboration
directed to diseases that align with Takeda’s core therapeutic areas of
interest. The unique collaboration will combine Schrödinger’s in
silico
platform-driven drug discovery capabilities with Takeda’s
deep therapeutic area knowledge and expertise in structural biology.
With a focus on simplicity, speed and agility, Schrödinger will lead the
multi-target discovery effort with Takeda providing protein crystal
structures to aid Schrödinger in using its computational platform to
guide the design of new chemical entities. Schrödinger will be
responsible for its discovery costs.







“Schrödinger’s agility, drug discovery track record and revolutionary
computational chemistry platform are key strengths that attracted Takeda
to Schrödinger as a strategic partner,” said Stephen Hitchcock, Ph.D.,
Head of Research for Takeda. “Takeda’s business model is focused on
creating mutually beneficial partnerships that capitalize on the
complementary capabilities of both parties in order to accelerate the
discovery of new therapies for patients. In this case, Schrödinger is
taking the lead role in discovery, with Takeda playing a supporting
role, leveraging its in-house structural biology team and therapeutic
area expertise.”



Under the terms of the collaboration, Takeda will have the option to
exclusively license the programs from Schrödinger later in discovery at
established economic terms, including pre-clinical, clinical, and
commercial milestones of up to $170M per program, as well as royalties
on future sales. Additional financial details are not being disclosed.



“We are very much looking forward to partnering with Takeda and
marshalling its biology and development expertise with our world class
computational chemistry and drug discovery capabilities to advance these
programs,” said Ramy Farid, Ph.D., Schrödinger’s President and Chief
Executive Officer. “This alliance allows us the opportunity to fully
exploit the power of our platform to accelerate the delivery of novel
therapeutics to patients.”



About Takeda Pharmaceutical Company



Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and central nervous system therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. New innovative products, especially
in oncology and gastroenterology, as well as Takeda’s presence in
Emerging Markets, are currently fueling the growth of Takeda. More than
30,000 Takeda employees are committed to improving quality of life for
patients, working with Takeda’s partners in health care in more than 70
countries. For more information, visit www.takeda.com/news.



About Schrödinger



Schrödinger is a leading provider of advanced molecular simulations and
enterprise software solutions and services to accelerate and increase
the efficiency of drug discovery for its clients, which include all
major pharmaceutical and biotechnology companies worldwide, as well as
leading materials science researchers. Schrödinger also establishes deep
partnerships and collaborations with companies in such fields as
biotechnology, pharmaceuticals, chemicals, and electronics, and was a
cofounder of leading biotech companies including Nimbus Therapeutics,
Morphic Therapeutic, and Relay Therapeutics. Schrödinger’s investors
include David E. Shaw and Bill Gates. Through significant long-term
investments in basic research, Schrödinger has made scientific
breakthroughs across many areas of drug discovery and materials science.
Hundreds of peer-reviewed scientific publications by Schrödinger
scientists are frequently among the most heavily cited in their fields.
Founded in 1990, Schrödinger has over 300 employees and operations in
the United States, Europe, Japan, and India, as well as business
partners in China and Korea. For more information, please visit www.schrodinger.com.



Takeda’s Forward-Looking Statements



This press release contains “forward-looking statements.”
Forward-looking statements include all statements other than statements
of historical fact, including plans, strategies and expectations for the
future, statements regarding the expected timing of filings and
approvals relating to the transaction, the expected timing of the
completion of the transaction, the ability to complete the transaction
or to satisfy the various closing conditions, future revenues and
profitability from or growth or any assumptions underlying any of the
foregoing. Statements made in the future tense, and words such as
“anticipate,” “expect,” “project,” “continue,” “believe,” “plan,”
“estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,”
“guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and
similar expressions are intended to qualify as forward-looking
statements. Forward-looking statements are based on estimates and
assumptions made by management that are believed to be reasonable,
though they are inherently uncertain and difficult to predict. Investors
and security holders are cautioned not to place undue reliance on these
forward-looking statements. Forward-looking statements involve risks and
uncertainties that could cause actual results or experience to differ
materially from that expressed or implied by the forward-looking
statements. Some of these risks and uncertainties include, but are not
limited to: required regulatory approvals for the transaction may not be
obtained in a timely manner, if at all; the conditions to closing of the
transaction may not be satisfied; competitive pressures and
developments; applicable laws and regulations; the success or failure of
product development programs; actions of regulatory authorities and the
timing thereof; changes in exchange rates; and claims or concerns
regarding the safety or efficacy of marketed products or product
candidates in development. The forward-looking statements contained in
this press release speak only as of the date of this press release, and
neither Schrödinger nor Takeda undertake any obligation to revise or
update any forward-looking statements to reflect new information, future
events or circumstances after the date of the forward-looking statement.
If one or more of these statements is updated or corrected, investors
and others should not conclude that additional updates or corrections
will be made.




Contacts


Takeda Contacts:
Tsuyoshi Tada – Japan
tsuyoshi.tada@takeda.com
+81-3-3278-2417
or
Kelly
Schlemm – USA
kelly.schlemm@takeda.com
+1-617-551-8865
or
Schrödinger
Contacts:
Investors:
Christina Tartaglia
Stern
Investor Relations, Inc.
TEL: +1-212-362-1200
or
Media:
Shi-Yi
Liu, Ph.D.
TEL: +1-503-299-1150 x108
shi-yi.liu@schrodinger.com

Evaluate Ltd's Epi Analyzer: Blockbusters Out, Highly Targe… 2017年07月20日 22時00分


New Case Studies Highlight Niche Patient Population Identification
and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi
Analyzer


LONDON & BOSTON & SAN FRANCISCO & TOKYO--(BUSINESS WIRE)--Today life science commercial intelligence leader, Evaluate, released case
studies
highlighting the value of granular patient segmentation and
epidemiological data to support commercial valuations, whitespace
identification and product differentiation ultimately leading to
enhanced portfolio decision-making. Therapy areas covered include:
CAR-T, MPS-III and Age-related Macular Degeneration.




According to report author and Evaluate Senior Analyst Chris Watson,
PhD, the last 5 years have witnessed a significant re-organisation of
the pharmaceutical business model around the ability to identify,
develop and bring to market novel therapies with proven clinical
benefits in very well defined patient populations.



“Within this rapidly changing environment, Evaluate is supporting our
clients with pioneering approaches to risk / value assessments and
forecasting, aimed to improve the quality and speed of analysis for
strategic decisions”, said Antonio Iervolino, Head of Forecasting at
Evaluate.



The case studies provide practical examples aimed at competitive
intelligence, business developers, corporate strategists and executive
decision-makers and demonstrate the value to these roles of convenient,
high quality epidemiology data used in conjunction with global
commercial intelligence.



Epi Analyzer, brings together Evaluate’s expertise in consensus
forecasts with a highly granular epidemiology database. Its coverage
includes over 160 diseases and 8,000 subpopulations with the ability to
drill down to very specific patient pools. To learn more and download the
case studies report, please visit: www.evaluate.com/EpiAnalyzerReport2017.



###



About Evaluate



Evaluate is the trusted provider of commercial intelligence including
product sales and consensus forecasts to 2022 for commercial teams and
their advisors within the global life science industry. We help our
clients make high value decisions through superior quality, timely,
must-have data and insights, combined with personalised, expert client
support. Our online subscription services cover the pharmaceutical,
biotech and medtech sectors. Our Custom Services group delivers project
based analytical and data services. EP Vantage, our independent,
award-winning editorial team, offers data-driven, forward-looking news,
commentary and analysis on a daily basis. For more information, please
visit: www.evaluategroup.com.
On Twitter: @evaluatepharma,
@evaluatemedtech,
@evaluateJP,
@epvantage.
On Instagram: Evaluateltd.


Contacts


Media Contacts:
Evaluate and EP Vantage (for general
questions)
Christine Lindgren
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Harris/Melanie Toyne Sewell
+44
(0) 20 7457 2020
evaluate@instinctif.com
or
Jani
Communications (for U.S. media)
Janice Foley
+1-617-823-5555
janifoley@verizon.net
or
Edelman
Japan KK
Yamada/Masaki
TEL: +81(3)-4360-9000
Email: EvaluateJapanPR@edelman.com

Neuland Laboratories Unveils Dedicated Process Engineering … 2017年07月20日 20時30分


Strengthens Quality by Design (QbD) Approach to Drug Substance
Manufacturing


HYDERABAD, India--(BUSINESS WIRE)--Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE-Scrip
Code:524558), a pharmaceutical manufacturer providing active
pharmaceutical ingredients
(APIs), complex intermediates and custom
manufacturing solutions services
to customers located in about 80
countries has brought online a fully operational dedicated Process
Engineering Lab at its R&D Center. The new lab includes state-of-the-art
instrumentation, systems and innovative devices to support operations
and safety studies using a QbD approach.








"Our new Process Engineering Lab integrates the key attributes of QbD
process understanding, process control, and continuous improvement with
advanced equipment, Design of Experiments Software, and Design Space
methodology, to optimize process design, operations, and productivity,"
says Saharsh Davuluri, Joint Managing Director at Neuland.



Neuland’s new Process Engineering Lab includes a stirred, controlled HEL
reaction calorimeter that measures the rate of heat release during
reactions. Automated parallel HEL reactors enable a chemist to perform
multiple experiments at temperatures ranging from -60 to 225oC.
The lab's new Thermal Screening Unit (TSU) indicates the thermal
stability of chemicals and safe processing temperatures. Ideal for risk
analysis, the TSU uses only 0.5-5 g of sample.



"This important addition to our capabilities will better enable Neuland
to develop cost-effective procedures and quality products, meet
regulatory requirements, improve scale-up efficiency, and accelerate
time to market," says Dr. Ravi Ponnaiah, President – Science &
Technology.



A QbD approach includes three fundamental elements: 1) a clear
understanding of the target product profile; 2) determination of
critical quality attributes (CQAs) and 3) ensuring that processes and
products remain within defined range limits. Continual risk assessment
of all aspects of a process, from the quality of the raw materials to
the process parameters and their potential effects on CQAs enables
continuous improvement of processes and products. A QbD program relies
on applying this information to develop a design space and a process
control strategy, continually monitoring the process to assess its
capabilities, introducing changes to improve product quality, cost, and
process efficiency.



About Neuland Laboratories Limited



Neuland Laboratories Limited, established in 1984, is headquartered in
Hyderabad, India, with offices in the U.S. and Japan. Neuland produces
quality APIs for customers across 80+ countries in more than 10 diverse
therapeutic segments. Along with generic drug products, Neuland offers
contract and custom manufacturing services for APIs and advanced
intermediates. The company has a stellar track record of successful
regulatory inspections from the U.S. Food and Drug Administration (FDA,
inspected 12 times), PMDA-Japan, EDQM, EMA, KFDA, TGA, ANVISA Brazil and
AFSSAPS (France), ISO9001, ISO14001, OHSAS18001 and ISO 27001. Current
regulatory filings exceed 650 with 51 USDMFs, 19 CEPs and 5 JDMFs.
Neuland has more than 523,000 L of reactor volume.



For more information, visit www.NeulandLabs.com.




Contacts


Brandwidth Solutions LLC
Debra Harrsch, 215-997-8575
dharrsch@brandwidthsolutions.com

世界トップレベルの国際オリーブオイルコンテスト「ソルドーロ… 2017年07月20日 13時00分


オリーブオイルビジネスをワンストップでカバーする国際専門見本市「第2回オリーブオイル関西国際商談専門見本市」(2017年10月11日(水)~13日(金))のプレイベントとして開催


大阪--(BUSINESS WIRE)--(ビジネスワイヤ) -- 世界で最も重要で権威あるオリーブオイルコンテストの一つである「ソルドーロ南半球
国際オリーブオイルコンテスト」(主催:ヴェローナ見本市会社)
が2017年9月11~15日に大阪市で開催されます。







この南半球のエクストラ・ヴァージンオリーブオイル生産者を対象とする「ソルドーロ南半球 
国際オリーブオイルコンテスト2017」が、チリ・南アフリカ・オーストラリアに続き、開催予定の「オリーブオイル関西2017」(2017年10月11日~13日、インテックス大阪、主催:一般財団法人大阪国際経済振興センター)のプレイベントとして、北半球の日本(大阪)へ特別招聘に成功し、開催します。



これにより、南半球の優れたオリーブオイルの生産者は、将来が非常に有望な消費市場として期待され、世界第4位のオリーブオイル輸入国である日本でマーケティングおよび商品プロモーションをする絶好の機会が得られることとなります。このため、日本および関西の食市場と業界に多大な影響と刺激を与える事となるでしょう。



「ソルドーロ南半球
国際オリーブオイルコンテスト」では、日本を含む世界7か国より総勢10名による著名なオリーブオイル鑑定士により厳格な審査が行われます。それにより、コンテストを通して世界最高のエクストラ・ヴァージンオリーブオイルの販売促進およびその生産と品質のさらなる向上を目指しています。厳正な審査と毎年同じ審査委員長の下で一貫した評価を行うという方針が功を奏し、受賞者は高品質なオイルの作り手として認められ、世界中のプロのバイヤーに注目されます。また、受賞オリーブオイルは、本コンテストの最終日となる2017年9月15日(金)12時からリーガロイヤルホテル大阪で開催される記者会見にて発表される予定です。



オリーブオイル関西2017 
国際商談専門見本市について



昨年世界13か国より78社が出展し好評だった「オリーブオイル関西 
国際商談専門見本市
」が今年もインテックス大阪にて開催されます。今年も著名な国内外のオリーブオイル専門家による特別セミナーなど多種多様な特別企画を実施します。



ソルドーロ南半球
国際オリーブオイルコンテスト
の主催者であり、イタリア・ヴェローナに本拠を置く国際見本市会社ヴェローナフィエレも出展します。今年9月に大阪市で開催されるソルドーロ南半球 
国際オリーブオイルコンテストで受賞した高品質なエクストラ・ヴァージンオリーブオイルのテイスティングセミナーを実施します。



開催概要
主催:一般財団法人大阪国際経済振興センター
日時:2017年10月11日(水)~13日(金)
場所:インテックス大阪
特別セミナースケジュール:3講演/日、3日間開催。(1講演、約1時間の予定。)
特別セミナー参加料金(予定):1枠¥3,000、1日券¥8,000、通し券¥20,000、各回定員50名(入替制)











































 


オリーブオイル関西2017」の併催特別企画(予定)



企画名

 

ハイライト

ビジターガイドテイスティングツアー


専門知識を要するオリーブオイルのプロフェッショナルをガイド役として各国のオリーブオイル、オリーブの品種、オリーブオイルの特徴など各種テーマで細分化して、来場者がオリーブオイルの理解と知識を更に深める事が出来る出展者ブース訪問ツアーです。

ライブクッキングデモ


日本料理や各国料理のシェフが出展者のオリーブオイルの魅力を最大限に引き上げる調理方法やレシピを伝授します。

出展社プレゼンテーション


出展社による自社ブランドオリーブオイルのプレゼンテーションを通し、多種多様なオイルや品種の魅力を披露します。

特別セミナー


国内外の著名な専門家を招き、多彩で実践的な内容のセミナーを実施します。

ビジネスマッチング(商談支援)サービス

 

開催前にコーディネーターが、来場予定者と出展者を繋ぎ、会期中の商談を設定および商談サポートをします。

 


「オリーブオイル関西」に関する情報は、http://www.olive-kansai.comからもご覧ください。



*インテックス大阪について
大阪を中心とする関西圏の経済発展と国際化を目的として1985年に設立され、今年(2017年)で開業32周年を迎えた。現在では、屋内総展示面積72,978m2、屋外展示面積2,900m2計9つの展示ホール、国際会議場、多数のミーティングルームを完備した国内で3番目且つ西日本最大の国際見本市会場である。開業以来、見本市・展示会を中心に3,200件余りの多種多様なイベントが開催された。また、これまで世界各国より延べ1億500万人を超えるビジターが来訪した。



*貴紙で当リリースを記事としてお取り上げいただければ大変幸甚に存じます。また、貴誌紙にご掲載くださいました際は、下記担当者までご送付いただきますようお願い申し上げます。




Contacts


【このプレスリリースに関する問い合せ先】
一般財団法人 大阪国際経済振興センター/オリーブオイル関西2017事務局
担当:樋渡 
知博
〒559-0034 大阪府大阪市住之江区南港北1-5-102
TEL:06-6612-8863 Email:info@olive-kansai.com
www.olive-kansai.com
※取材のお問い合せは、担当までご連絡お願いいたします

Hasegawa Hotel & Resort: Y's Cabin Osaka Namba Grand Openin… 2017年07月20日 11時30分


First in Osaka to be opened in Dotonbori in heart of Minami


TOKYO--(BUSINESS WIRE)--Y’s Cabin Osaka Namba, a new 162-room cabin hotel constructed by
Hasegawa Hotel & Resort Co., Ltd. (Toshima-ku, Tokyo; Representative
Director: Natsuki Abe) in Dotonbori, Chuo-ku, Osaka (one-minute walk
from Namba St., Midosuji Subway Line), will start operations on
Wednesday, August 9.






New hotel style called “cabin hotel”





Cabin hotel is a new type of accommodation that delivers higher quality
than capsule hotels at more reasonable prices than budget hotels while
ensuring safety.



(Regular price: 4,500 yen -> 3,200 yen for limited time only)*



Located within a minute’s walk from Namba subway station, Y’s Cabin
Osaka Namba is close to Ebisu Bridge famous for the Glico Man sign and
Kani Douraku crab restaurant as well as Kuromon shopping mall and other
popular sightseeing spots. Easily accessible from Kansai International
Airport, it is a great choice as a base for sightseeing in Kyoto as well.



* Limited time only and rooms are subject to availability; This rate
applies to bookings made by end of August.



Enhanced measures for inbound tourists
(1) Foreign
language-speaking staff
(2) Currency exchange machine
(3)
Separate security by gender
(4) Free Wi-Fi



Y’s Cabin Osaka Namba
URL: https://ys-cabin.com/osaka-namba/en/
FB:
@yscabinosakananba



-------------------------------------------------------
Y’s Cabin
Yokohama Kannai opened in Tokyo-Yokohama area last October!
Last
October, Hasegawa Hotel & Resort opened Y’s Cabin Yokohama Kannai, a
great place to stay for sightseeing. It has been a popular pick for
international visitors.
URL: https://ys-cabin.com/yokohama-kannai/
FB:
@yscabin.yokohamakannai
-------------------------------------------------------




Contacts


Hasegawa Hotel & Resort Co., Ltd.
Akihito Shimaguchi,
+81-3-5956-1320 (main)
FAX: +81-3-5992-0064



Mitsubishi Electric Corporation Named in FTSE4Good Index Se… 2017年07月20日 11時10分

TOKYO--(BUSINESS WIRE)--Mitsubishi
Electric Corporation
(TOKYO:6503) announced today that it has been
named as a constituent of the FTSE4Good Index Series, a world-leading
socially responsible investment (SRI) indicator developed by FTSE
Russell, a part of the London Stock Exchange Group.




The FTSE4Good Index Series comprises companies that demonstrate strong
environmental, social and governance (ESG) practices. Players in global
stock markets use the indices as SRI indicators to determine if
investment funds and other products are socially responsible and engage
in ethical activities.



Mitsubishi Electric is committed to achieving the sustainable
development goals (SDGs) introduced by the United Nations in 2015. The
Mitsubishi Electric Group will make continuous innovation as a part of
its efforts to achieve even higher growth as a "global, leading green
company" that contributes to the creation of a prosperous society where
both a "sustainable society" and "safe, secure, and comfortable
lifestyles" are simultaneously achieved, as expressed in the corporate
statement, Changes for the Better.



About Mitsubishi Electric Corporation



With over 90 years of experience in providing reliable, high-quality
products, Mitsubishi Electric Corporation (TOKYO:6503) is a recognized
world leader in the manufacture, marketing and sales of electrical and
electronic equipment used in information processing and communications,
space development and satellite communications, consumer electronics,
industrial technology, energy, transportation and building equipment.
Embracing the spirit of its corporate statement, Changes for the Better,
and its environmental statement, Eco Changes, Mitsubishi Electric
endeavors to be a global, leading green company, enriching society with
technology. The company recorded consolidated group sales of 4,238.6
billion yen (US$ 37.8 billion*) in the fiscal year ended March 31, 2017.
For more information visit:
www.MitsubishiElectric.com
*At
an exchange rate of 112 yen to the US dollar, the rate given by the
Tokyo Foreign Exchange Market on March 31, 2017




Contacts


Mitsubishi Electric Corporation
Customer Inquiries
CSR
Promotion Center
Corporate Administration Division
Tel:
+81-3-3218-3623
www.MitsubishiElectric.com/contact/index.html
or
Media
Inquiries

Arisa Mori, +81-3-3218-2810
Public Relations
Division
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/



FUJIFILM Corporation Announces Results from Phase II Clinic… 2017年07月19日 17時30分

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (TOKYO: 4901) (President: Kenji Sukeno) announced
that the company’s Alzheimer’s Disease drug “T-817MA,” did not meet its
primary study endpoints of cognition or global clinical function in its
Phase II clinical trial conducted in the United States on patients with
mild to moderate Alzheimer’s Disease (AD). There were no significant
differences in secondary outcomes. In exploratory analyses, change of
the cerebrospinal fluid (CSF) biomarker phospho-tau (p-Tau) benefited
from the higher dose treatment while hippocampal*1 volumes
decreased less in the lower doses group with statistical significance.
Post hoc analyses also suggested T-817MA treatment with shorter duration
of illness and symptoms was associated with better cognitive outcomes
with statistical significance. Fujifilm will review the results of the
Phase II clinical trial with regulatory authorities including FDA (U.S.
Food and Drug Administration) and will take necessary steps toward
further development including Phase III clinical trial of this compound.




A pre-clinical research, led by Dr. Rudolph Tanzi, Joseph P. and Rose F.
Kennedy Professor of Neurology at Harvard Medical School, and Vice-Chair
of Neurology at Massachusetts General Hospital, revealed that T-817MA
acts on microglia*2 that have a risk gene for AD and promotes
the clearance of amyloid-β (Aβ).
These results suggest that T-817MA
may act on p-Tau and Aβ, major causal substances in AD.



AD’s main symptoms are abnormalities in cognitive functions, including
memory. It is believed that abnormality of neurological functions in AD
manifests as a result of Aβ protein deposits (senile plaques) in the
brain. The progression of the disease has strong association with the
formation of abnormal assemblies caused by hyperphosphorylation and
fibrillization of tau proteins, found in the axons of nerve cells
(neurofibrillary tangle), synapse*3 loss and atrophy of the
brain including hippocampus.
The number of people suffering from
dementia is estimated to be 44 million around the world. The number is
projected to increase to 76 million by 2030 with the aging of the world
population. Over half of these dementia cases suffer from AD, and the
trend is set to continue.
AD drugs currently available on the
market include acetylcholinesterase inhibitors, such as donepezil
hydrochloride. As these drugs address the deficit in neurotransmission
to give temporary improvement to the patients' symptoms, there is an
unmet need for a new class of therapies to treat AD.



T-817MA is an AD drug discovered by the Fujifilm Group company, Toyama
Chemical. It has potent neuroprotective effect and promotes neurite
outgrowth through the activation of sigma receptors*4,
demonstrating strong efficacy in animal models. Fujifilm is committed to
further accelerating the development of T-817MA under possible
partnerships, and contributing to resolving social challenges through
the delivery of innovative pharmaceutical products.


































 

 

*1

 

Hippocampus is a region of the cerebrum, associated with memory. AD
causes neuronal loss, which results in hippocampal atrophy.


*2


Microglia are a type of glia cells, which are component of the
central nervous system. Microglia provide immune defense in the
brain, while also being involved in repairing abnormal neural cells,
and eliminating the aggregated Aβ. At the same time, excessively
activated microglia are known to play a role in neuro-degeneration
in the central nervous system.


*3


Synapse is a structure connecting neurons, allowing them to pass
electrical signals to convey information between them.


*4


Sigma receptors are protein that exists on the membrane of
endoplasmic reticulum in cells, and have the function of mitigating
neuro-degeneration in the central nervous system.

 



Contacts


For enquiries on information in this media release, contact:
Media
contact

FUJIFILM Corporation
Kana Matsumoto, +81
3-6271-2000
Corporate Communications Division
Other
FUJIFILM
Corporation
Pharmaceutical Products Division
TEL +81
3-6271-2171



Toshiba Wins a Stay for Temporary Restraining Order on Tosh… 2017年07月19日 16時59分

TOKYO--(BUSINESS WIRE)--The California Court of Appeal in San Francisco has ruled that Toshiba
Corporation (TOKYO:6502) may resume efforts to protect its intellectual
property and deny Western Digital workers access to certain data and
facilities effective immediately.




The court on July 18 (US time) issued a stay on a temporary restraining
order granted last week that required Toshiba to provide such access. As
Toshiba stated last week, this is a proceeding with many rounds and many
rulings. This particular ruling allows Toshiba Memory Corporation (TMC)
to reaffirm its commitment to protecting its intellectual property and
prevent Western Digital employees from accessing confidential
information stored in its databases, an action Toshiba has already
implemented.


Contacts


Press Contact
Toshiba Corporation
Kaori Hiraki,
+81-3-3457-2100
Public Relations & Investor Relations Div.
Media
Relations Group
media.relations@toshiba.co.jp

パナソニックがゼテス・インダストリーズSAの買収および非上場… 2017年07月19日 15時30分

大阪--(BUSINESS WIRE)--(ビジネスワイヤ) -- パナソニック株式会社(本社:大阪府門真市、代表取締役 社長:津賀 一宏、以下:パナソニック)は、ベルギー
ブリュッセルに本社を置き、物流・人物認証とモビリティソリューションのマーケットリーダーであるゼテス・インダストリーズSA(Zetes
Industries SA:以下「ゼテス社」)の発行済株式100%の取得と、同社の非上場化を完了したことをお知らせいたします。




本買収はパナソニックが力を入れるB2Bソリューション分野の中の重点領域の一つである「物流」において大変重要な意味を持つものです。当社は、今後、倉庫などの省人化、省力化を可能とする物流ソリューションをより強化してまいります。加えて、公共分野でのID発行などのセキュリティ対策に貢献する人物認証ソリューションの展開もあり、お客様価値創造による当社のグローバルでの持続的な成長に大きく寄与すると考えています。



今回の非上場化を受け、当社はゼテス社との、より迅速で強い連携を実現し、両社でのビジネス展開を加速していきます。具体的には、ゼテス社が強みを持つ物流ソリューション分野において、当社の先端研究開発力を融合し、ビジネスの拡大を進めてまいります。加えて、ゼテス社のソリューションの日本をはじめとするグローバル市場への展開についても、ゼテス社と具体的な検討を進めております。



今後、両社は、物流・人物認証ならびにモビリティソリューション事業の成長を強力に推進し、この分野におけるリーディング・プロバイダーとしての地位の確立を目指します。



なおゼテス社は、パナソニックグループの一員として、Alain
Wirtz(アラン・ウィルツ)氏が率いる現経営陣の下、ゼテスブランドで引き続き事業を展開していきます。



(本件買収の経緯)
パナソニックは、2017年4月28日、相対取引によりゼテス社の発行済株式の57.01%を取得し、その後、ベルギー法に基づく義務的公開買付け(TOB)を開始しました。同TOBの結果、2017年6月22日には、発行済株式の95%以上を保有するに至りましたので、スクイーズアウト手続を行い、本日、発行済株式の100%の取得を完了いたしました。なお、本日のプレスリリースに先立ち、2017年7月13日、ゼテス社のユーロネクスト・ブリュッセルにおける株式上場は廃止となっています。




Contacts


【お問い合わせ先】
<報道関係者様>
パナソニック(株) コネクティッドソリューションズ社
広報部 
蓑原(みのはら)、山田
電話 06-6905-4006



Panasonic Successfully Completes the Acquisition and De-lis… 2017年07月19日 15時30分

OSAKA, Japan--(BUSINESS WIRE)--#Zetes--Panasonic Corporation announced today that it has completed the
acquisition of 100% of outstanding shares of Zetes Industries SA and the
de-listing of Zetes shares from Euronext Brussels. Zetes is
headquartered in Brussels, Belgium and has a market leading position in
goods and people identification and mobility solutions in Europe.




This acquisition is an important milestone for Panasonic’s logistics
business, one of the key segments in the growing B2B Solutions business.
The transaction allows Panasonic to further strengthen its logistics
solutions capabilities that help its logistic clients to increase the
effectiveness and efficiency of their operations. In addition, Panasonic
also intends to expand people identification solutions, which include
the design, production and personalization of secure ID documents for
the public sector. Panasonic believes that this transaction will
contribute significantly to its global capabilities delivering
sustainable growth and customer value.



Following the de-listing, Panasonic is able to closely cooperate with
Zetes and to accelerate the business development of both companies.
Specifically, Panasonic plans to integrate its advanced research and
development capabilities with Zetes’s market leading goods
identification solutions. Together with Zetes, Panasonic is also
actively exploring further business expansion beyond Europe, including
Japan.



Both, Panasonic and Zetes are committed to pursuing further growth in
goods and people identification and mobility solutions to become the
leading provider in these markets.



Zetes will continue to operate under the Zetes brand as part of the
Panasonic Group and to be managed by the existing management team led by
Mr. Alain Wirtz.



On April 28, 2017, Panasonic completed the acquisition of 57.01% of
Zetes's issued shares in a private transaction and subsequently launched
a mandatory takeover bid under Belgian law. On June 22, 2017, Panasonic
held more than 95% of the issued shares as a result of the takeover bid
and subsequently reopened the bid as a squeeze-out. As of today,
Panasonic successfully completed the acquisition of 100% ownership of
Zetes. Prior to this announcement, Zetes’s shares were delisted from
Euronext Brussels on July 13, 2017.



About Panasonic
Panasonic
Corporation is a worldwide leader in the development of diverse
electronics technologies and solutions for customers in the consumer
electronics, housing, automotive, and B2B businesses. Celebrating its 100th
anniversary in 2018, the company has expanded globally and now operates
495 subsidiaries and 91 associated companies worldwide, recording
consolidated net sales of 7.343 trillion yen for the year ended March
31, 2017. Committed to pursuing new value through innovation across
divisional lines, the company uses its technologies to create a better
life and a better world for its customers. To learn more about
Panasonic: http://www.panasonic.com/global.




Contacts


Media Contact:
Global Communications Department
Panasonic
Corporation

Tel: +81-(0)3-3574-5664



Toyoda Gosei Develops New Side Airbag 2017年07月19日 14時00分


For Improved Vehicle Safety


KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. has jointly developed a new side airbag together
with Toyota Motor Corporation. The new airbag contributes to vehicle
crash safety assessment conformity in each region of the world and can
be shared by various vehicle models. It is used on the new Camry and is
scheduled for future use on about 2.5 million vehicles annually,
including other models.








Side airbags are mounted by the side of the seat (door side). They
lessen impacts to the chest and abdomen by deploying instantaneously
between the door trim and passenger during side impacts.



Conventional side airbags were structured of two separate airbags, but
the new airbag has a three-bag structure for instantaneous deployment in
high-speed crashes and efficient impact absorption. The internal
pressure of each of the three bags is optimized for each vehicle model,
so that these airbags can be used on a variety of models from large to
small vehicles.



About Toyoda Gosei



Established in 1949 and headquartered in Kiyosu, Aichi Prefecture,
Japan, Toyoda Gosei is a leading specialty manufacturer of rubber and
plastic automotive parts and LEDs. Today, the Toyoda Gosei Group
provides a variety of high-quality products internationally, with a
network of approximately 100 plants and offices in 18 countries and
regions. Through its flexible, integrated global supply system and
leading-edge technologies for automotive safety, comfort, and
environmental preservation, Toyoda Gosei is a global supplier that
aims to deliver the highest levels of quality, innovation, and
satisfaction to customers worldwide
.




Contacts


Toyoda Gosei Co., Ltd.
Takatomo Abe
inquiry@mail.toyoda-gosei.co.jp



Mitsubishi Electric to Support Relief Efforts Following Sev… 2017年07月19日 11時10分

TOKYO--(BUSINESS WIRE)--Mitsubishi
Electric Corporation
(TOKYO:6503) announced today that Mitsubishi
Electric Group companies will donate a total of five million yen
(approximately US$ 44,600) to aid victims of a severe rainstorm that hit
Japan’s northern Kyushu region on July 5.




The Mitsubishi Electric Group expresses its deepest sympathies to those
affected by the disaster and extends its sincerest wishes for a speedy
recovery.



About Mitsubishi Electric Corporation
With
over 90 years of experience in providing reliable, high-quality
products, Mitsubishi Electric Corporation (TOKYO:6503) is a recognized
world leader in the manufacture, marketing and sales of electrical and
electronic equipment used in information processing and communications,
space development and satellite communications, consumer electronics,
industrial technology, energy, transportation and building equipment.
Embracing the spirit of its corporate statement, Changes for the Better,
and its environmental statement, Eco Changes, Mitsubishi Electric
endeavors to be a global, leading green company, enriching society with
technology. The company recorded consolidated group sales of 4,238.6
billion yen (US$ 37.8 billion*) in the fiscal year ended March 31, 2017.
For more information visit:
www.MitsubishiElectric.com
*At
an exchange rate of 112 yen to the US dollar, the rate given by the
Tokyo Foreign Exchange Market on March 31, 2017




Contacts


Mitsubishi Electric Corporation
Media Inquiries
Arisa
Mori, +81-3-3218-2810
Public Relations Division
prd.gnews@nk.MitsubishiElectric.co.jp
www.MitsubishiElectric.com/news/



Prana Commences Research Collaboration with Takeda for the … 2017年07月18日 22時00分


PBT434, Prana’s lead drug in preclinical development for movement
disorders, to be profiled in collaborative venture


MELBOURNE, Australia & SAN FRANCISCO--(BUSINESS WIRE)--Prana Biotechnology Ltd (ASX:PBT)(NASDAQ:PRAN) today announced a
research collaboration with Takeda Pharmaceuticals International, Inc.
to study the ability of Prana’s investigational movement disorders
compound, PBT434, to slow or prevent neurodegeneration of the
gastrointestinal system.




One of the important non-motor features of Parkinson’s disease is often
the early presentation of severe and disabling impairment of
gastrointestinal function. Parkinson’s disease is characterised by the
loss of neurons and their networks in the brain and in the gut. The
cause of neurodegeneration and gastrointestinal dysfunction in
Parkinson’s disease is not known, but the protein alpha-synuclein has
been hypothesized to be implicated in this process.



Prana recently announced the publication of results with PBT434
demonstrating significant reduction of alpha-synuclein in various
pre-clinical models of Parkinson’s disease in the paper entitled, “The
novel compound PBT434 prevents iron-mediated neurodegeneration and
alpha-synuclein toxicity in multiple models of Parkinson’s disease”
in
the peer reviewed journal Acta Neuropathologica Communications *. This
paper suggested that PBT434 may reduce the formation of toxic
alpha-synuclein fibrils and aggregates, rescue neurons burdened by such
toxic forms of alpha-synuclein and restore motor function in animal
models.



The research collaboration will investigate the ability of
investigational compound PBT434 to mitigate gastrointestinal
dysfunction; constipation, lowered colon motility and inflammation in
mouse models, including an alpha-synuclein transgenic mouse.



Associate Professor David Finkelstein, Prana’s Senior Scientific
Consultant and Head of the Parkinson’s Disease Laboratory at the Florey
Institute of Neuroscience and Mental Health (Melbourne), said: “This
early research is important because our major therapeutic objective is
to treat these disabling symptoms and provide an early therapeutic
intervention for both motor and non-motor Parkinsonian symptoms in
patients which may significantly impact on the quality of life.”



PBT434 is the first of a new generation of small molecules from the
quinazolinone class of drugs that was specifically designed to block the
accumulation and aggregation of alpha-synuclein and is expected to begin
human testing in a Phase 1 trial later this year.



*The peer reviewed article can be accessed from: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-017-0456-2



About Prana Biotechnology Limited
Prana Biotechnology was
established to commercialise research into neurodegenerative diseases
such as Alzheimer's disease, Huntington disease, and Parkinsonian
disease. The Company was incorporated in 1997 and listed on the
Australian Stock Exchange in March 2000 and listed on NASDAQ in
September 2002. Researchers at prominent international institutions
including The University of Melbourne, The Mental Health Research
Institute (Melbourne) and Massachusetts General Hospital, a teaching
hospital of Harvard Medical School, contributed to the discovery of
Prana’s technology.



For further information please visit the Company’s web site at www.pranabio.com.




Contacts


for Prana Biotechnology
Investor Relations
WE Buchan
Rebecca
Wilson, +61 3 9866 4722
rwilson@buchanwe.com.au
or
Media
WE
Buchan
Scott Newstead, +61 3 9866 4722
snewstead@buchanwe.com.au



LINE Corporation: Notice of Confirmation of Terms for the I… 2017年07月18日 20時21分

TOKYO--(BUSINESS WIRE)--With respect to the issuance of stock options (warrants) resolved at the
meeting of the Board of Directors of LINE Corporation
(NYSE:LN)(TOKYO:3938) (Headquarters: Shinjuku-ku, Tokyo, Japan;
President & CEO: Takeshi Idezawa; the “Company”) held June 26, 2017,
certain previously undetermined items have been confirmed as follows.




1. LINE Corporation 20th Warrants



(1) Total number of warrants: 12,621 allotments



(2) Paid-in amount for warrants



154,500 yen per warrant (1,545 yen per share of stock)
Persons who
have been allotted warrants shall set off his/her claims for
remuneration against the Company in lieu of payment of monies for the
warrants allotted.






































 


(3)



 


Categories and Numbers of Warrant Allottees as well as Total
Warrants Allotted





 



Allottee

 

Number

 

Number of Warrants



Directors of the Company

 

Four (4)

 

12,621

 


2. LINE Corporation 21st Warrants



(1) Total number of warrants: 11,239 allotments



(2) Paid-in amount for warrants



154,500 yen per warrant (1,545 yen per share of stock)
Persons who
have been allotted warrants shall set off his/her claims for
remuneration against the Company in lieu of payment of monies for the
warrants allotted. For directors at the subsidiaries of the Company
(“Subsidiary Directors”) who have been allotted warrants, the Company
assumes the remuneration obligation of the Company's subsidiary, and
offsets the Subsidiary Directors’ claims for remuneration against the
Company in lieu of payment of monies for the warrants allotted.
























































 


(3)



 


Categories and Numbers of Warrant Allottees as well as Total
Warrants Allotted





 



Allottee

 

Number

 

Number of Warrants



Executive officers of the Company


Nine (9)


9,436



Director of one of the Company’s subsidiaries


One (1)


1,803



Total

 

Ten (10)

 

11,239

 


If there are any conflicts of the terms in Japanese and English of this
document, the terms in Japanese shall prevail.


Contacts


LINE Global PR
Icho Saito, +81-3-4316-2104
dl_gpr@linecorp.co

Zymeworks and Daiichi Sankyo Announce Successful Achievemen… 2017年07月18日 18時00分

VANCOUVER, British Columbia, TOKYO and BASKING RIDGE, N.J.--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
next-generation bispecific and multifunctional biotherapeutics,
initially focused on the treatment of cancer, and Daiichi Sankyo
Company, Limited (“Daiichi Sankyo”) today announced the successful
achievement of a research milestone for an immuno-oncology bispecific
antibody therapeutic candidate in their collaboration. In conjunction
with this milestone achievement, Zymeworks is to receive a milestone
payment of one million dollars from Daiichi Sankyo.






Under the terms of their existing agreement signed on September 26,
2016, Zymeworks granted Daiichi Sankyo a license to Zymeworks’
Azymetric™ and EFECT™ platforms to develop a bispecific antibody
therapeutic for which Zymeworks is eligible to receive preclinical,
clinical and commercial milestone payments, as well as up to
double-digit tiered royalties on global product sales. Additionally,
Zymeworks obtained a license to certain immuno-oncology antibodies from
Daiichi Sankyo, with the right to research, develop and commercialize
multiple bispecific products globally in exchange for royalties on
global product sales.



We are very excited by the rapid progress we have made in our
collaboration with Daiichi Sankyo, which further demonstrates the
versatility and biophysical robustness of the Azymetric™ platform, and
we continue to work closely with Daiichi Sankyo towards advancing this
potential immuno-oncology therapeutic towards the clinic,” said Dr. Ali
Tehrani, President and CEO of Zymeworks. “In parallel, we are continuing
to develop and advance other novel immunomodulatory bispecific
antibodies incorporating the immuno-oncology antibodies that were
in-licensed from Daiichi Sankyo to expand Zymeworks’ pipeline of
therapeutic candidates.”



We are pleased that we have been able to reach this research milestone
for the development of this bispecific antibody with Zymeworks,” said
Toshinori Agatsuma, Ph.D., Vice President, Biologics & Immuno-Oncology
Laboratories at Daiichi Sankyo. “We look forward to continued success
with this collaboration to help strengthen our bispecific antibody
development capabilities in order to help change the standard of care
for patients with cancer.”



About the Azymetric™ Platform
The Azymetric™ platform
consists of a library of proprietary amino acid substitutions that
enable the transformation of monospecific antibodies into bispecific
antibodies, which gives them the ability to simultaneously bind two
non-overlapping epitopes, or antigens. Azymetric™ bispecific technology
enables the development of biotherapeutics with dual-targeting of
receptors/ligands and simultaneous blockade of multiple signaling
pathways, increasing tumor-specific targeting and efficacy while
reducing toxicities and the potential for drug-resistance. Additionally,
the dual-targeting of Azymetric™ antibodies has demonstrated synergistic
efficacy in preclinical studies through simultaneous binding relative to
the application of an equivalent dose of the corresponding monospecific
antibodies. Azymetric™ bispecifics can also be engineered to enhance
internalization of the antibody into the tumor cell and consequently
increase the delivery of cytotoxic payloads.



First-generation bispecific platforms significantly alter the structure
of monoclonal antibodies or rely upon complex and proprietary
manufacturing processes. Azymetric™ bispecifics, in contrast, retain the
desirable drug-like qualities of monoclonal antibodies, including long
half-life, stability and low immunogenic potential, which increases
their probability of success. Azymetric™ bispecifics are also compatible
with standard manufacturing processes with high yields and purity, which
accelerates manufacturing timelines and reduces costs.



About the EFECT™ Platform
The EFECT™ platform is a library
of antibody Fc region modifications engineered to modulate the activity
of the antibody-mediated immune response, which includes both the up and
down-regulation of effector functions. This platform is compatible with
traditional monoclonal antibodies as well as Azymetric™ bispecific
antibodies, which further enables the customization of therapeutic
responses for different diseases.



About Zymeworks Inc.
Zymeworks is a clinical-stage
biopharmaceutical company dedicated to the discovery, development and
commercialization of next-generation multifunctional biotherapeutics,
initially focused on the treatment of cancer. Zymeworks’ suite of
complementary therapeutic platforms and its fully-integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly-differentiated product candidates.
Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody
currently being evaluated in an adaptive Phase 1 clinical trial.
Zymeworks is also advancing a deep pipeline of preclinical product
candidates and discovery-stage programs in immuno-oncology and other
therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its
therapeutic platforms have been further leveraged through multiple
strategic partnerships with global biopharmaceutical companies.



About Daiichi Sankyo Cancer Enterprise
The vision of Daiichi
Sankyo Cancer Enterprise is to leverage our world-class, innovative
science and push beyond traditional thinking in order to create
meaningful treatments for patients with cancer. We are dedicated to
transforming science into value for patients, and this sense of
obligation informs everything we do. Anchored by our Antibody Drug
Conjugate (ADC) and Acute Myeloid Leukemia (AML) Franchises, our cancer
pipeline includes more than 20 small molecules, monoclonal antibodies
and ADCs stemming from our powerful research engines: our two
laboratories for biologic/immuno-oncology and small molecules in Japan,
and Plexxikon Inc., our small molecule structure-guided R&D center in
Berkeley, CA. Compounds in development include: quizartinib, an oral
FLT3 inhibitor, for newly-diagnosed and relapsed/refractory AML with
FLT3-ITD mutations; DS-8201, an ADC for HER2-expressing breast and
gastric cancer, and other HER2-expressing solid tumors; and
pexidartinib, an oral CSF-1R inhibitor, for tenosynovial giant cell
tumor (TGCT), which is also being explored in a range of solid tumors in
combination with the anti-PD1 immunotherapy pembrolizumab. For more
information, please visit: www.DSCancerEnterprise.com.



About Daiichi Sankyo
Daiichi Sankyo Group is dedicated
to the creation and supply of innovative pharmaceutical products to
address diversified, unmet medical needs of patients in both mature and
emerging markets. With over 100 years of scientific expertise and a
presence in more than 20 countries, Daiichi Sankyo and its 15,000
employees around the world draw upon a rich legacy of innovation and a
robust pipeline of promising new medicines to help people. In addition
to a strong portfolio of medicines for hypertension and thrombotic
disorders, under the Group’s 2025 Vision to become a “Global Pharma
Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo
research and development is primarily focused on bringing forth novel
therapies in oncology, including immuno-oncology, with additional focus
on new horizon areas, such as pain management, neurodegenerative
diseases, heart and kidney diseases, and other rare diseases. For more
information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a
member of the Daiichi Sankyo Group. For more information on Daiichi
Sankyo, Inc., please visit: www.dsi.com.



Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and "forward-looking
information" within the meaning of Canadian securities laws, or
collectively, forward-looking statements. Forward-looking statements
include statements that relate to the clinical development of Daiichi’s
immuno-oncology bispecific antibody therapeutic candidate, the
advancement of other bispecific antibodies or Zymeworks’ product
candidate pipeline, Daiichi collaboration progress and other information
that is not historical information. When used herein, words such as
“progress”, “continue”, “advancing”, “potential”, “expand”, and similar
expressions are intended to identify forward-looking statements. In
addition, any statements or information that refer to expectations,
beliefs, plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon our current expectations and various
assumptions. We believe there is a reasonable basis for our expectations
and beliefs, but they are inherently uncertain. We may not realize our
expectations, and our beliefs may not prove correct. Actual results
could differ materially from those described or implied by such
forward-looking statements as a result of various factors, including,
without limitation, market conditions and the factors described under
“Risk Factors” in our registration statement on Form F-1 and in our
supplemented PREP prospectus dated April 27, 2017 filed in connection
with our initial public offering on May 3, 2017 (copies of which filings
may be obtained at www.sec.gov
and www.sedar.com).
Consequently, forward-looking statements should be regarded solely as
our current plans, estimates and beliefs. You should not place undue
reliance on forward-looking statements. We cannot guarantee future
results, events, levels of activity, performance or achievements. We do
not undertake and specifically decline any obligation to update,
republish or revise any forward-looking statements to reflect new
information, future events or circumstances or to reflect the
occurrences of unanticipated events, except as may be required by law.




Contacts


Zymeworks:
David Poon, Ph.D.
Executive Director,
External R&D and Alliances
(604) 678-1388
bd@zymeworks.com
or
Investor
Inquiries:
David Matousek
Senior Manager, Investor Relations &
Corporate Communications
(604) 678-1388
ir@zymeworks.com
or
Daiichi
Sankyo:

Jennifer Brennan
Director, Global Product
Communications
Daiichi Sankyo, Inc.
+1 908 992 6631 (office)
+1
201 709 9309 (mobile)
jbrennan2@dsi.com

Renesas Electronics Wins Patent Infringement Lawsuit Filed … 2017年07月18日 15時00分

TOKYO--(BUSINESS WIRE)--#Renesas--Renesas Electronics Corporation (TSE: 6723, “Renesas”), a premier
supplier of advanced semiconductor solutions, today announced that on
July 14, 2017 EDT, the United States District Court for the District of
Massachusetts (Boston), ruled in favor of Renesas Electronics
Corporation and Renesas Electronics America Inc., a wholly-owned
subsidiary of Renesas, in a patent infringement lawsuit brought against
it by Zond, LLC (based in Massachusetts) filed on July 8, 2013.




In July 2013, Zond brought suit against multiple semiconductor companies
and others including Renesas and Renesas Electronics America, alleging
that the companies infringed eight of its U.S. patents (one of which was
later withdrawn at Zond’s request) covering production-related
technologies such as plasma discharge. Renesas and other defendants
challenged the patentability of Zond’s remaining patents in inter partes
reviews (IPR) with the Patent Trial and Appeal Board (PTAB) of the
United States Patent and Trademark Office (USPTO). By January 2016, all
seven patents had been ruled unpatentable by the PTAB. Zond appealed the
rulings to the United States Court of Appeals for the Federal Circuit
(CAFC), but later Zond voluntarily dismissed some of those appeals. On
January 18, 2017, CAFC upheld the PTAB’s rulings for the remaining
patents. Zond did not appeal the CAFC’s decision to the U.S. Supreme
Court, and thus the unpatentability of the patents became final.



Following the decision concluding unpatentability of the Zond patents,
on July 14, 2017 EDT, United States District Court for the District of
Massachusetts entered final judgment in favor of Renesas and Renesas
Electronics America.



Moving forward, Renesas, while maintaining its basic stance of respect
for intellectual property rights, will resolutely defend itself against
improper claims of patent infringement or infringement of intellectual
property rights.



About Renesas Electronics Corporation



Renesas Electronics Corporation (TSE:
6723
) delivers trusted embedded design innovation with complete
semiconductor solutions that enable billions of connected, intelligent
devices to enhance the way people work and live—securely and safely. The
number one global
supplier of microcontrollers, and a leader in Analog & Power and SoC
products, Renesas provides the expertise, quality, and comprehensive
solutions for a broad range of Automotive, Industrial, Home Electronics
(HE), Office Automation (OA) and Information Communication Technology
(ICT) applications to help shape a limitless future. Learn more at renesas.com.


Contacts


Japan
Renesas Electronics Corporation
Kyoko Okamoto, +
81-3-6773-3001
kyoko.okamoto.sx@renesas.com

Murata Partners with STMicro to Add SigFox Connectivity to … 2017年07月18日 12時00分

KYOTO, Japan--(BUSINESS WIRE)--Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) today
announced the results of its collaboration with both STMicro
and SigFox
to port the SigFox stack to co-exist alongside the LoRa stack on
Murata’s small form factor Type
ABZ
LoRaWAN™ module. With this feature Murata has extended the
module’s capability for providing both LoRa and SigFox capabilities
worldwide from a single hardware platform. This approach allows
customers to decide which network technology serves the application best
depending on location, service requirements and cost.








Both networks offer similar low-power wide area network (LPWAN)
capabilities, targeting applications in smart meters, facility
management, asset tracking, and a range of other uses in the IoT space.
While each has differences, the common goal is network coverage with
good Quality of Service (QoS). By supporting both standards, Murata’s
module can also bridge both networks, providing even greater deployment
flexibility by allowing a dual-mode operation from a single firmware
package that can be used globally.



As the first major vendor to offer an LPWAN module that supports both
LoRa and SigFox, Murata expects to achieve a leading position in this
market while giving customers greater solution longevity and robustness.
For example, in the event of a network problem on one network,
customer applications would be able to easily switch to the other
protocol, this offering redundancy of communications links.



Currently, Murata’s Type ABZ LoRaWAN™ module, which uses an STMicro
STM32-based wireless microcontroller and SX1276 Semtech RFIC, operates
in the 806-930MHz frequency band and provides a nominal output power of
+14 dBm that can be boosted to +20 dBm for long range or poor signal
location applications. STMicro is a key partner for Murata, and STMicro
are responsible for the development of the SigFox firmware. SigFox
European certification of the module has been completed and
certification for the US and Asia-Pacific regions is scheduled to be
completed next. The firmware will be made available by STMicro through
its website.



“We are very excited to collaborate with STMicroelectronics on launching
Murata’s LoRa/SigFox dual mode module into the LPWA ecosystem”, said
Samir Hennaoui, Product Manager at Murata. “By combining these two
complementary technologies, we have produced a module suitable for the
many different kinds of applications our customers wish to use it for.
The interoperability of the module will also encourage new customers to
enter the market.”



For more information to check stocks, please visit
http://www.murata.com/en-sg/support/stock?partnumber1=CMWX1ZZABZ?excid=as_pr-p_dt_ttl_bw-lpwa_20170718



More about Murata’s wireless products can be viewed at:
http://wireless.murata.com/eng/products.html?excid=as_pr-p_dt_ttl_bw-lpwa_20170718



About Murata
Murata Manufacturing Co., Ltd. is a worldwide
leader in the design, manufacture and sale of ceramic-based passive
electronic components & solutions, communication modules and power
supply modules. Murata is committed to the development of advanced
electronic materials and leading edge, multi-functional, high-density
modules. The company has employees and manufacturing facilities
throughout the world. For more information, visit Murata's website at www.murata.com




Contacts


Media Contact
Murata Manufacturing Co., Ltd.
Junko
Matsumura, +81-75-955-6786
Corporate Communications Office
prsec_mmc@murata.com



SAISON INFORMATION SYSTEMS: DataSpider Servista Empowers IT… 2017年07月18日 11時30分


New version further enables rapid implementation of large-scale data
integration


TOKYO--(BUSINESS WIRE)--Saison Information Systems Co., Ltd. (JASDAQ:9640) (Headquarters: Tokyo,
Japan; CEO: Kazuhiro Uchida; herein, “Saison Information Systems”) will
release version 4.1 of DataSpider Servista, the data integration
platform developed its wholly owned subsidiary, Appresso Co., Ltd.
(Headquarters: Tokyo, Japan; CEO: Kazutoshi Ono; herein “Appresso”), on
July 31, 2017.




The latest version brings enhancements to the core data integration
capabilities of DataSpider Servista Version 4, which was developed to
serve the needs of the IoT era. It further strengthens the platform’s
efficiency and productivity in all phases of design, development, and
testing, enabling rapid implementation of large-scale data integration
projects while reducing costs.



About DataSpider Servista



As of March 2017, DataSpider Servista has been installed by over 3,000
companies. In Japan, it has been ranked No. 1 in customer satisfaction
for four years in a row*. Its GUI enables quick and easy setup without
the need for coding. Its many adapters can connect a wide variety of
systems, applications, databases, and other data sources hosted either
on-premise or in the cloud. It can be used to automate a broad range of
processes, thereby significantly improving an organization’s operational
efficiency.



(* Source: Nikkei BP Consulting Survey of EAI Software, April 2017)
Product
Details: https://www.hulft.com/en/dataspider-servista



About Appresso Co., Ltd.




  • Headquarters: Sumitomo Fudosan Edogawabashi Ekimae Building (2F),
    1-20-10 Sekiguchi, Bunkyo-ku, Tokyo 112-0014, Japan


  • CEO: Kazutoshi Ono (CEO & Representative Director)


  • Capital: ¥267 million


  • Business Activities: Development and support of software packages


  • Website: https://www.appresso.com/english/



About Saison Information Systems Co., Ltd.




  • Headquarters: Sunshine 60 (21F), 3-1-1 Higashi-Ikebukuro, Toshima-ku,
    Tokyo 170-6021, Japan


  • Established: September 1970


  • President: Kazuhiro Uchida (President & CEO)


  • Website: http://home.saison.co.jp/english/



Trademarks




  • ”DataSpider,” and “DataSpider Servista” are trademarks of Appresso
    Co., Ltd.


  • Other names of companies, products, and services are trademarks of
    their respective companies.




Contacts


HULFT Media Inquiries
Saison Information Systems Co., Ltd.
Akane
Toyota / Seiko Yokoi, +81-3-3988-3477
Corporate Planning Department
kikaku@saison.co.jp
or
HULFT
Product Inquiries

Saison Information Systems Co., Ltd.
Masaaki
Takayama, +81-3-3988-5301
HULFT Division
info@hulft.com



Mitsubishi UFJ Financial Group, Inc. Announces Filing of An… 2017年07月18日 11時00分

TOKYO--(BUSINESS WIRE)--Mitsubishi UFJ Financial Group, Inc.
(NYSE:MTU)(TOKYO:8306)(ISIN:JP3902900004)(MUFG) hereby announces that it
has filed its Annual Report on Form 20-F for the fiscal year ended March
31, 2017 (the “Annual Report”) with the U.S. Securities and Exchange
Commission on July 14, 2017. The Annual Report includes MUFG’s audited
consolidated financial statements prepared under U.S. GAAP as of and for
the fiscal year ended March 31, 2017.




The Annual Report is available on our website at the following website
address:
http://www.mufg.jp/english/ir/form20-f/



In addition, all shareholders may receive a hard copy of the Annual
Report free of charge upon request at our website. Such request should
be made to below:
https://form.hd.mufg.jp/regist/is?SMPFORM=nbp-lergt-4cdffa98f29ce1e48fbe39a625e48382




Contacts


Mitsubishi UFJ Financial Group, Inc.
Kazutaka Yoneda,
+81-3-3240-3110
General Manager-Financial Planning Division,
Financial
Accounting Office

Toshiba Updates on the Preliminary Injunctive Relief Brough… 2017年07月18日 10時07分



  • At the July 14 hearing, the Superior Court of California did not
    rule on Western Digital’s injunction request.



  • Instead, the court suggested the companies to work on generating an
    agreement on the court’s proposal for Toshiba providing with two
    weeks’ advance notice on closing its memory business sales, provided
    this occurs before the arbitration panel is formed under the ICC Rules.



  • The arbitration panel should be formed within the next few months,
    while Toshiba’s targets closing the memory business sale for March end
    in 2018.



  • In the meantime, Toshiba can continue to negotiate and sign an
    agreement with bidders for the memory business.



TOKYO--(BUSINESS WIRE)--Toshiba Corporation (TOKYO:6502) has today filed an update to the Tokyo
Stock Exchange and Nagoya Stock Exchange on the court hearing on July 14
at the Superior Court of California for the County of San Francisco (the
Court), on the motion for preliminary injunctive (PI) relief made by
SanDisk LLC (SanDisk), a subsidiary of Western Digital Corporation
(Western Digital) (NASDAQ:WDC).




At the July 14 hearing, the Judge proposed a solution and did not order
a PI. Instead, the Judge proposed Toshiba give two weeks’ notice to
SanDisk before Toshiba closes the sale of its memory business (the Deal)
for the period until the arbitration panel can be formed. Arbitration
was initiated by SanDisk in May 2017. Pursuant to the ICC (International
Chamber of Commerce) Rules that govern the arbitration, the tribunal
should be formed within the next few months.



As both sides agreed to the approach if it can be properly worded, the
Judge requested the parties to negotiate language that would implement
the Judge’s proposal and present that to the Court by July 28.



Toshiba agreed not to close the Deal before the July 28 hearing. Given
that regulatory approval for the Deal will likely take several months
after signing, Toshiba’s current target is to close the Deal by the end
of March 2018. As a result, there is no chance of closing the Deal
within the next two weeks.
In the meantime, Toshiba can and will
continue to negotiate and sign an agreement with bidders for the Deal.



The company looks forward to the next hearing currently scheduled for
July 28.




Contacts


Press Contact
Toshiba Corporation
Kaori Hiraki,
+81-3-3457-2100
Public Relations & Investor Relations Div.
Media
Relations Group
media.relations@toshiba.co.jp

SoftBank and WeWork Announce Joint Venture to Transform Wor… 2017年07月18日 07時00分

TOKYO & NEW YORK--(BUSINESS WIRE)--The SoftBank Group and WeWork Companies (“WeWork”) today announced a
joint venture that will bring WeWork’s transformational platform of
space, community, and services for companies of all sizes – including
creators, entrepreneurs, small and medium businesses, and large
multinational enterprises – to Japan. The SoftBank Group1 and
WeWork will each own 50% of the joint venture, which will operate under
the name of WeWork Japan. By entering Japan, WeWork will expand its
global community and connect its more than 130,000 members to the
innovative and growing Japanese market.







“Driven by Adam’s superior vision and his highly talented team, WeWork
is disrupting preconceived notions of work styles and opening up myriad
opportunities for the next generation of creators around the world by
taking a scientific approach that fully utilizes the latest
technologies,” said Masayoshi Son, Chairman & CEO of SoftBank Group
Corp. “With this joint venture, we look forward to collaborating with
WeWork to offer new possibilities for people in Japan.”



“At WeWork, we want to create a world where people work to make a life,
not just a living,” said Adam Neumann, Co-Founder and CEO of WeWork.
“When I met Masa and understood his vision for a technology-enabled
future, a vision I share, I knew that together we would be able to make
a big impact, grow our community and change how and where people work.
Both WeWork and SoftBank have established reputations for connecting
people and creating partnerships to facilitate innovation and inspire
new ideas. SoftBank shares our tenacity and entrepreneurial spirit and
through collaboration we will work to benefit people and communities in
many innovative ways. We are only as strong as our people and partners,
so we look forward to our future with SoftBank, welcoming Japan into our
global community and helping more creators and businesses to collaborate
and innovate together in ways they could not yet imagine."



WeWork, a platform for creators, has created an extensive global network
of shared workspaces. The company provides an entirely new way to work
by offering flexible space, services, and a connected community network
to creators, entrepreneurs, small and medium businesses, and
multinational companies. WeWork’s “space as a service” solution enables
companies of all sizes to enter and exit markets opportunistically, grow
and shrink office footprints according to their needs, and pursue new
business lines and ideas in a way that best suits their particular
needs. In offering its services in Japan, WeWork hopes to build
connections between non-Japanese members of WeWork’s global network and
the creators and businesses that drive the world’s third largest economy.



In the last year, WeWork has diversified its product offering to better
accommodate the needs of enterprise companies. Today, more than 10% of
Fortune 500 companies are members with WeWork. This segment represents
the fastest growing member demographic for WeWork and it now accounts
for more than 20% of WeWork’s total membership, indicating the enormous
potential for encouraging large and well-established companies to
collaborate and innovate within WeWork’s member community.



WeWork is committed to challenging outdated ways of building, using, and
interacting with physical space in a working environment. To do this, it
deploys industry-leading software and technology to maximize the
efficiency of its portfolio of workspace locations and its operations,
and thereby increase member satisfaction. The Company also uses
data-driven analytics to better understand how people operate in the
workplace and uses these insights to develop its product and create an
even more compelling offering for its members. As one of the few
end-to-end product companies that acts as an owner, operator, and client
organization, WeWork has developed proprietary technological data
systems that can source, design, and ultimately manage buildings.



WeWork is creating a digital operating system for physical space that
leverages data and technology at each point in the building process so
it can make better sourcing decisions, improve its designs, build faster
and smarter, and ultimately improve the lives of the people working
within its buildings. Its cutting-edge technologies and dedication to
technological innovation is one of the key reasons why WeWork has been
able to scale from operating one workspace location to more than 150 in
just over seven years.



WeWork plans to launch its first location in Tokyo in early 2018. To
oversee this launch and scale its Japanese operations, WeWork has
appointed Chris Hill to serve as the Chief Executive Officer of WeWork
Japan. Chris joined WeWork in 2010 shortly after its founding to serve
as the company’s first Chief Operating Officer. During his tenure at
WeWork, Chris has held several key executive functions, which include
serving as the Global Head of Community and Operations and, most
recently, serving as the Global Chief Community Officer. In these roles,
Chris has created, implemented, and scaled many of the processes,
operational frameworks, and strategies that are used to run WeWork
communities and create the highest level of member experience. Over the
past two years, Chris has spent extensive time overseas successfully
scaling the WeWork brand in foreign markets.



About the SoftBank Group



SoftBank is a global technology player that aspires to drive the
Information Revolution. SoftBank is comprised of the holding company
SoftBank Group Corp. (TYO: 9984), its domestic telecommunications
subsidiary SoftBank Corp., and its global portfolio of companies, which
includes advanced telecommunications, internet services, AI, smart
robotics, IoT and clean energy technology providers. In September 2016,
ARM Holdings plc, the world’s leading semiconductor IP company, joined
the SoftBank group. To learn more, please visit www.SoftBank.jp/en/



About WeWork



WeWork is a platform for creators, providing more than 130,000 members
around the world with space, community, and services through both
physical and virtual offerings. WeWork’s mission is to help create a
world where people work to make a life, not just a living. WeWork
currently has more than 150 physical locations in 49 cities and 15
countries around the world. WeWork, started in New York City in 2010,
was founded by Adam Neumann and Miguel McKelvey.



1 A subsidiary of SoftBank Group Corp. (SBG) and SoftBank
Corp., a subsidiary of SBG and a telecom operating company in Japan,
will contribute to the joint venture.


Contacts


Media
SoftBank
Japan:
SoftBank
Group
SoftBank Group Corp. Corporate Communications
+81 3 6889
2300
sbpr@softbank.co.jp
or
US:
Sard
Verbinnen & Co
Benjamin Spicehandler / Hannah Dunning
+1
212-687-8080
SoftBank-SVC@sardverb.com
or
WeWork
Dominic
McMullan / Rebecca McClain
press@wework.com

Japan Cookware Market 2016-2023 - Research and Markets 2017年07月18日 00時20分

DUBLIN--(BUSINESS WIRE)--The "Cookware
Market: Japan 2017"
report has been added to Research
and Markets'
offering.




There has been a lot of product innovation in recent years; with the
increase in competition and fear of market stagnation, many companies
are turning towards technology to enhance their products. A variety of
colorful cookware and cast iron ceramic pans are quickly becoming more
popular.



For the purposes of this research, cookware is defined as utensils used
on the top of stove for cooking purposes.



Cookware products include:



- Pressure cookers



- Woks



- Stockpots



- Fry pans



- Saucepans



- Casseroles



- Griddles



- Grill pans



- Dutch ovens



- Steamers



- Omelet pans



- Chestnut pans



- Sauté pans



Materials include:



- Stainless steel



- Aluminium



- Cast iron



- Copper



- Nonstick coatings



Key Topics Covered:



I. Scope of Research/Definitions



II. Cookware Market: Japan



a. Country Profile



b. Market Measurements.



c. Market Drivers.



d. Market Restraints



e. Pricing Trends.



f. Market Trends



III.Market Data



a. Market Share by Revenue, by Cookware Type



b. Market Share by Revenue, by Cookware Material.



c. Market Share by Revenue, by Distribution



d. Total Japan Cookware Market: Revenue Forecasts, 2016-2023



e. Market Share by Revenue.



f. Premium Stainless Steel Cookware Market: Revenue Forecasts, 2016-2023



g. Market Share by Revenue, Premium Stainless Steel Cookware Market



h. Regular Stainless Steel Cookware Market: Revenue Forecasts, 2016-2023



i. Market Share by Revenue, Regular Stainless Steel Cookware Market



j. Premium Nonstick Cookware Market: Revenue Forecasts, 2016-2023.



k. Market Share by Revenue, Premium Nonstick Cookware Market



l. Regular Nonstick Cookware Market: Revenue Forecasts, 2016-2023.



m. Market Share by Revenue, Regular Nonstick Cookware Market



n. Others Cookware Market: Revenue Forecasts, 2016-2023.



o. Market Share by Revenue, Others Cookware Market



Companies Mentioned



- Amway



- Fissler Japan Ltd.



- Groupe SEB



- MEYER Japan Co. Ltd.



- Vita Craft Japan Ltd.



- WMF Japan Consumer Goods Co. Ltd.



- Zwilling JA Henkels Japan Co. Ltd.



For more information about this report visit https://www.researchandmarkets.com/research/fncz4m/cookware_market




Contacts


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Household,
Household
Appliances

NAMSA Launches Japanese Website to Support Increased Demand… 2017年07月17日 09時05分

TOKYO--(BUSINESS WIRE)--#clinicalresearch--NAMSA,
the world’s only Medical Research Organization (MRO) that accelerates
medical device development through integrated laboratory, clinical and
consulting services is excited to announce the launch of its newly
developed Japanese
website
.




The introduction of this highly-anticipated website is a direct result
of the increased demand for NAMSA’s integrated medical device
development services throughout Japan. Generating $53.2B in the medical
device equipment market in 2016, Japan ranks as the world’s third
largest medical product marketplace and is expected to grow steadily
through 2020 (GlobalData).



“We’re extremely pleased to launch our first ever Japanese website to
better serve our clients. This user-friendly and information-filled
resource will not only help support our significant growth in Japan, but
will also allow Japanese manufacturers to more easily identify a proven,
single source solution
for efficient and cost-effective medical device development,” commented
Terry Tsuji, General Manager, NAMSA Japan.



NAMSA, with two Japanese office locations
in Kyoto and Tokyo, provides clients with highly sought after testing,
clinical and regulatory services required to accelerate medical device
development and market introduction.



Japanese medical device manufacturers wishing to learn more about
NAMSA’s services are encouraged to visit http://namsa.co.jp/
or to email NAMSA’s team of experts at japansales@namsa.com.



About NAMSA



NAMSA is
a Medical Research Organization (MRO), accelerating medical device
product development through integrated laboratory, clinical and
consulting services. Driven by our regulatory expertise, NAMSA’s MRO®
Approach plays an important role in translational research, applying a
unique combination of disciplines – consulting, regulatory, preclinical,
toxicology, microbiology, chemistry, clinical and quality – to move
clients’ products through the development process, and continue to
provide support through commercialization to post-market requirements
anywhere in the world.



NAMSA operates 13 offices throughout North America, Europe, the Middle
East and Asia, and employs nearly 1,000 highly-experienced laboratory,
clinical and consulting Associates.



Follow us on Twitter,
LinkedIn or Facebook for
regular updates.




Contacts


NAMSA
Leah Davidson, 612-615-6985
Marketing Communications
Manager
ldavidson@namsa.com

NAMSA、医療機器開発サービスの需要増をサポートするため日本語… 2017年07月17日 09時05分

東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 統合的なラボ・臨床・助言サービスを通じて医療機器開発を加速する世界で唯一の医学研究組織(MRO)であるNAMSAは、新たな日本語ウェブサイトを立ち上げることを発表します。




この期待の高いウェブサイトの開設は、NAMSAの統合医療機器開発サービスの日本全域における需要増を直接反映したものです。2016年に医療機器市場で532億ドルを生み出した日本は、世界第3位の医療製品市場であり、2020年まで着実に成長すると期待されています(GlobalData)。



NAMSAジャパンのゼネラルマネジャーのテリー・ツジは、次のように述べています。「お客さまにより良いサービスを提供すべく、初の日本語ウェブサイトを開設できることを非常にうれしく思います。この利用しやすく情報満載のウェブサイトは、日本での大幅な成長を支え、日本のメーカーは今後、効率的で費用対効果の高い医療機器開発に向けた実証済みの単一ソースソリューションをより簡単に特定できるようになります。」



京都と東京に2つの事務所を構えるNAMSAは、医療機器の開発と市場投入を加速させるために必要な非常に需要の高い検査・臨床・規制サービスをお客さまに提供しています。



NAMSAのサービスの詳細をご希望の日本の医療機器メーカーは、http://namsa.co.jp/をご覧になるか、NAMSAの専門家チームまで電子メール(japansales@namsa.com)でご連絡ください。



NAMSAについて



NAMSAは医学研究組織(MRO)として、統合的なラボ・臨床・助言サービスを通じて医療機器の製品開発を加速しています。規制に関する専門知識が推進するNAMSAのMRO®アプローチは、橋渡し研究で重要な役割を果たしています。お客さまの製品開発プロセスを通じて助言、規制、前臨床、毒物学、微生物学、化学、臨床、品質の各分野のユニークな組み合わせを適用し、世界のあらゆる場所で製品化や市販後の要件まで継続してサポートします。



NAMSAは、北米、欧州、中東、アジアの全域に13カ所の事務所を構え、約1000人のラボ、臨床、助言の経験豊富なアソシエートを雇用しています。



ツイッター、リンクトイン、フェイスブックで当社をフォローし、最新情報を入手してください。



本記者発表文の公式バージョンはオリジナル言語版です。翻訳言語版は、読者の便宜を図る目的で提供されたものであり、法的効力を持ちません。翻訳言語版を資料としてご利用になる際には、法的効力を有する唯一のバージョンであるオリジナル言語版と照らし合わせて頂くようお願い致します。




Contacts


NAMSA
Leah Davidson, 612-615-6985
Marketing Communications
Manager
ldavidson@namsa.com

Western Digital’s SanDisk Subsidiaries Obtain Court Protect… 2017年07月15日 09時18分

SAN JOSE, Calif.--(BUSINESS WIRE)--Western Digital Corp. (NASDAQ: WDC) today announced that the Court of
California for the County of San Francisco (“the Court”) directed
Toshiba Corporation (“Toshiba”) not to transfer its interests in its
three NAND flash-memory joint ventures (“the JVs”) operated with Western
Digital’s SanDisk subsidiaries without specified advance notice to
SanDisk, in order to ensure that the issue is preserved for arbitration.
Today’s hearing was held in connection with the preliminary injunctive
relief proceedings sought by SanDisk related to Toshiba’s attempts to
transfer its JV interests.




Steve Milligan, chief executive officer of Western Digital, stated, “We
are grateful for today’s directive by the Court, which is a victory for
Western Digital, SanDisk and our stakeholders. Our entire goal was to
preserve and protect our rights through the binding arbitration process,
and that’s precisely what the Court has done today. This is the second
time this week that the Court has acted to protect SanDisk’s rights and
interests against Toshiba.”



About Western Digital



Western Digital is an industry-leading provider of storage technologies
and solutions that enable people to create, leverage, experience and
preserve data. The company addresses ever-changing market needs by
providing a full portfolio of compelling, high-quality storage solutions
with customer-focused innovation, high efficiency, flexibility and
speed. Our products are marketed under the HGST, SanDisk and WD brands
to OEMs, distributors, resellers, cloud infrastructure providers and
consumers. Financial and investor information is available on the
company's Investor Relations website at investor.wdc.com.



Forward-Looking Statements



This news release contains certain forward-looking statements, including
statements concerning the JVs, SanDisk’s rights under the JV agreements,
its actions to protect such rights, and ongoing proceedings with respect
to those rights. There are a number of risks and uncertainties that may
cause these forward-looking statements to be inaccurate including, among
others: uncertainties with respect to the company's business ventures
with Toshiba; volatility in global economic conditions; business
conditions and growth in the storage ecosystem; impact of competitive
products and pricing; market acceptance and cost of commodity materials
and specialized product components; actions by competitors; unexpected
advances in competing technologies; our development and introduction of
products based on new technologies and expansion into new data storage
markets; risks associated with acquisitions, mergers and joint ventures;
difficulties or delays in manufacturing; and other risks and
uncertainties listed in the company's filings with the Securities and
Exchange Commission (the "SEC"), including the company's Form 10-Q filed
with the SEC on May 8, 2017, to which your attention is directed. You
should not place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and the company undertakes no
obligation to update these forward-looking statements to reflect
subsequent events or circumstances.




Contacts


United States
Media Contact:
Jim
Pascoe
408-717-6999
jim.pascoe@wdc.com
or
Investor
Contact:
Bob Blair
949-672-7834
robert.blair@wdc.com
or
Joele
Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Jed Repko / Ed
Trissel
415-869-3950 / 212-355-4449
wdcmedia@joelefrank.com
or
Japan
Media
Contacts:
Emi Hatano
090-5765-9730
emi.hatano@sandisk.com
or
Ashton
Consulting
John Sunley / Brendan Jennings
03 5425-7220 /
090-7416-0180 / 050 7576-6190
WDC_JapanPR@ashton.jp



企業をしらべれば人生が変わる! -就活やビジネスを成功に導くユーレット活用術-
スポンサードリンク
Ullet経審

他社比較

help他社比較するには?


注目情報

他社比較
「味の素はどっち?」いろんな会社を比較してみよう!
Ulletニュース
過去の掲載記事等の一覧。

マイリスト

ページ

ここに企業名をドラッグ&ドロップすると、リストに追加することが出来ます。

戻る次へ

閲覧履歴

ページ

ここに閲覧した企業の履歴が表示されます。

戻る次へ

関連サービス

Ulletモバイル
何時でもどこでも携帯で見れる!
Ullet経審 New
160,000社の決算書データ公開。売上高や評点別ランキングも。
aera 西野グローバルIT研究所 環境新聞・ユーレット合同企画『CO2と経営』
Ulletモバイル試験運用開始 QRコードを読込